Menu
Enrolling by invitation NCT06924996

Efficacy and Safety of Endovascular Thrombectomy in Acute Ischemic Stroke With Posterior Circulation Large Infarct

Observational Acute Basilar Artery Occlusion Posterior Circulation Large Infarct

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Endovascular Thrombectomy (EVT).
Who it may be relevant to
Registry conditions: Acute Basilar Artery Occlusion, Posterior Circulation Large Infarct. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Efficacy and Safety of Endovascular Thrombectomy in Acute Ischemic Stroke With Posterior Circulation Large Infarct: A Multicenter, Prospective, Cohort Study

Overview

The purpose of this study is to evaluate whether endovascular thrombectomy (EVT) combined with best medical management (BMM) leads to better functional outcomes than BMM alone in patients with acute basilar artery occlusion with posterior circulation large infarct.

Detailed description

This study is a multicenter, prospective, cohort study that prospectively enrolled consecutive patients with acute basilar artery occlusion and large core infarction in the posterior circulation, confirmed by imaging (CTA/MRA/DSA). Written informed consent was obtained from all participants or their legal representatives prior to enrollment. Patients were divided into the best medical management (BMM) group and the endovascular thrombectomy (EVT) group according to the treatment they received. This study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

Interventions

  • Procedure Endovascular Thrombectomy (EVT)
    A maximum of six attempts to retrieve the thrombus in a single vessel can be made with any Solitaire AB/FR device or aspiration. In case an atherosclerotic lesion is found underlying the occlusive lesion, angioplasty and subsequent stenting through detachment of the Solitaire device will be allowed

Primary outcome measures

  • Rate of modified Rankin scale 0-3 at 90 (±14) days after enrollment [Time frame: 90 (±14) days]
Secondary outcome measures (3)
  • Ordinal Shift analysis of mRS score at 90 (±14) days after enrollment [Time frame: 90 (±14) days]
  • Rate of mRS 0-2 at 90 (±14) days after enrollment [Time frame: 90 (±14) days]
  • Rate of Functional health status and quality of life (EuroQol Five Dimensions) at 90 (±14) days after enrollment [Time frame: 90 (±14) days]

Eligibility criteria

Inclusion criteria

  • Age 18-80 years old;
  • Acute ischemic stroke in the posterior circulation, the onset of stroke (or last well known) to the enrollment time within 24 hours;
  • CTA/MRA/DSA confirmed acute basilar artery occlusion;
  • Posterior circulation large infarct: NCCT or DWI showed pc-ASPECTS ≤ 5 points, or pontine midbrain index (PMI) ≥ 3 points;
  • NIHSS score ≥10 points after the onset of the stroke and before enrollment;
  • Able to live independently before the onset of the disease (mRS score ≤2 points);
  • The subject or legal representative is able to sign the informed consent form.

Exclusion criteria

  • Intracranial hemorrhage (except microhemorrhage) on CT/MRI ;
  • CT/MRI revealed large infarction in the cerebellar hemisphere, with significant mass effect causing compression of the fourth ventricle or brainstem;
  • CT or MRI showed bilateral complete thalamic infarction;
  • Occlusion of anterior and posterior circulation arteries confirmed by CTA/MRA/DSA;
  • The presence of intracranial tumors (except for small meningiomas and cerebral aneurysms with a diameter of <3mm);
  • Patients with known or highly suspected chronic basilar artery occlusion.;
  • Known severe allergy to contrast agents (except for mild rash);
  • Refractory hypertension (defined as systolic blood pressure > 185 mmHg or diastolic blood pressure >110 mmHg) that cannot be controlled by drug therapy;
  • Known pregnant or lactating females, or positive pregnancy test before enrollment;
  • Acute cerebral infarction within 48 hours after cardiovascular and cerebrovascular intervention or major surgery (patients more than 48 hours can be enrolled).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Beijing Tiantan Hospital — Beijing

Identifiers

NCT: NCT06924996 · KY2023-106-02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗